Blackhill Capital’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Blackhill Capital’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-28,000	Closed	-$63K	–	59
2020 Q3	$63K	Hold	28,000	–	–	0.01%	53
2020 Q2	$100K	Hold	28,000	–	–	0.01%	53
2020 Q1	$106K	Hold	28,000	–	–	0.02%	56
2019 Q4	$84K	Buy	+28,000	New	+$72.8K	0.01%	60

Other funds holding BMY.RT

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BFS

Bard Financial Services Branford, Connecticut $911M AUM 19.14% 1-Year Est. Return

LGP

Leonard Green & Partners Los Angeles, California $2.77B AUM 3.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Blackhill Capital's BMY.RT Position: Q4 2020 in Review

Blackhill Capital sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q4 2020, closing a stake of 28,000 shares — an estimated $63K sold.

Blackhill Capital first reported a position in BMY.RT in Q4 2019 and held it in 4 quarters. The position peaked at $106K in Q1 2020. 546 funds tracked by Wall St. Rank hold BMY.RT as of Q4 2020.

Blackhill Capital reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q4 2020 after selling out during the quarter.
Blackhill Capital sold 28,000 Bristol-Myers Squibb Company Contingent Value Rights shares in Q4 2020, an estimated $63K.
Blackhill Capital first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 4 quarters.
Blackhill Capital's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $106K in Q1 2020.
546 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q4 2020.

Based on Blackhill Capital's 13F filing for Q4 2020, filed 8 Feb 2021.